Good morning :)
Place Order
Add to Watchlist

Brooks Laboratories Ltd

BROOKS

Brooks Laboratories Ltd

BROOKS
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹403 cr, stock is ranked 1,964
High RiskStock is 4.41x as volatile as Nifty
153.562.00% (-3.14)
153.562.00% (-3.14)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹403 cr, stock is ranked 1,964
High RiskStock is 4.41x as volatile as Nifty

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹403 cr, stock is ranked 1,964
High RiskStock is 4.41x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-22.996.14
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.236.560.48%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Brooks Laboratories Ltd. is a Contract Manufacturing Company. The Company manufacturers molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2021FY 2022FY 2023FY 2024TTM
Total Revenue77.9991.9863.7780.4582.69
Raw Materialssubtract51.7766.2847.4556.5997.63
Power & Fuel Costsubtract2.703.993.231.73
Employee Costsubtract12.0416.8516.0010.09
Selling & Administrative Expensessubtract6.218.576.214.05
Operating & Other expensessubtract4.019.7520.0424.93
Depreciation/Amortizationsubtract7.147.357.031.771.73
Interest & Other Itemssubtract3.103.102.180.840.83
Taxes & Other Itemssubtract10.38-12.61-17.470.030.03
EPS-7.76-4.53-8.38-7.65-6.68
DPS0.000.000.000.000.00
Payout ratio0.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Brooks Laboratories Ltd-20.586.14
Divi's Laboratories Ltd90.7410.700.55%
Syngene International Ltd70.178.400.14%
Aarti Pharmalabs Ltd27.493.390.46%

Price Comparison

Compare BROOKS with any stock or ETF
Compare BROOKS with any stock or ETF
BROOKS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.16%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding63.59%3.86%0.00%0.00%32.55%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

JunAugSepDec '23MarJun0.00%0.00%0.00%0.00%0.00%0.00%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 2 Mutual Funds holding Brooks Laboratories Ltd



Funds (Top 2)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Business Cycle Fund - Growth - Direct Plan

Growth
2.8754%0.78%0.45%27/48 (-9)
Quant Healthcare Fund - Growth - Direct Plan

Growth
0.0000%0.00%-1.39%4/30 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

BROOKS has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Brooks Laboratories to conduct AGM

Brooks Laboratories announced that the 22th Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Brooks Laboratories to hold AGM

Brooks Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 19 September 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Brooks Laboratories reports consolidated net loss of Rs 2.41 crore in the June 2024 quarter

Net Loss of Brooks Laboratories reported to Rs 2.41 crore in the quarter ended June 2024 as against net loss of Rs 4.47 crore during the previous quarter ended June 2023. Sales rose 14.20% to Rs 17.93 crore in the quarter ended June 2024 as against Rs 15.70 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales17.9315.70 14 OPM %-10.71-24.90 - PBDT-2.01-4.03 50 PBT-2.41-4.47 46 NP-2.41-4.47 46 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Brooks Laboratories schedules board meeting

Brooks Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live

Brooks Laboratories reports consolidated net loss of Rs 4.68 crore in the September 2022 quarter

1 year agoBusiness Standard

Capital Trust Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

Brooks Laboratories’ subsidiary gets marketing authorization in Germany for Meropenem

2 years agoIndia Infoline

Raj Oil Mills Ltd leads gainers in ‘B’ group

3 years agoBusiness Standard

Gyscoal Alloys Ltd leads losers in ‘B’ group

3 years agoBusiness Standard

Brooks Laboratories to make new investments in JV to build integrated global carbapenem biz

3 years agoIndia Infoline